Cycloalkylamine derivatives as NK-1/SSRI antagonists

Details Cycloalkylamine derivatives as NK-1/SSRI antagonists Cycloalkylamine derivatives as NK-1/SSRI antagonists

2005-07-18

2009-02-24

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S450000

Reexamination Certificate

active

07494986

ABSTRACT:
The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compoundsuseful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

REFERENCES:
patent: 6136824 (2000-10-01), MacLeod et al.
patent: 7067507 (2006-06-01), Pulley et al.
patent: WO 99/62900 (1999-12-01), None
patent: WO 2004/005255 (2004-01-01), None
patent: WO 2004/005256 (2004-01-01), None
patent: WO 2004/022539 (2004-03-01), None
patent: WO 2004/056771 (2004-07-01), None
“Depression-signs, syptoms, help, and treatment”, http://www.helpguide.org/mental/depression—signs—types—diagnosis—treatment.htm, accessed Dec. 29, 2007.
Murthy et al. Expert Opinion on Therapeutic Patents, 1998, 8(7), 785-818.
Dell'Osso et al. Expert Opinion on Pharmacotherapy, 2005, 6(15), 2727-40.
Amadesi et al. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1206-11.
Stevenson, G.I., et al., “4,4-Dissubstituted Piperidines: A New Class of NK1Antagonist”,J. Med. Chem. 1995, 38 1264-1266.
Stevenson, G.I. et al., “4,4-Dissubstituted Piperidine High-Affinity NK1Antagonists: Structure-Activity Relationships andin VivoActivity”,J. Med. Chem. 1998, 41, 4623-4635.
Kramer, Mark S., et al., “Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors”,Science, 281 (1998) 1640-1645.
Maubach, Karen A., et al., “Novel Strategies for Pharmacotherapy of Depression”,Current Opinion in Chemical Biology, 3 (1999) 481-488.
Rosen, Terry J., et al., “Synthesis and Structure-Activity Relationships of CP-122,721, A Second-Generation NK-1 Receptor Antagonist”, ,Bioorganic & Medicinal Chemistry Letters, 8 (1998) 281-284.
Ryckmans, Thomas, et al., “First Dual NK1Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants”,Bioorganic & Medicinal Chemistry Letters, 12 (2002) 261-264.

Affiliated with

Also associated with

Rating

Cycloalkylamine derivatives as NK-1/SSRI antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cycloalkylamine derivatives as NK-1/SSRI antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkylamine derivatives as NK-1/SSRI antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4073943